Neurocrine Biosciences Inc (NBIX)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell
$134.30
Buy
$161.00
$0.14 (+0.10%)
Prices updated at 19 Dec 2025, 00:22 EST
| Prices minimum 15 mins delay
Prices in USD
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 98.56 |
| 2023 | 97.90 |
| 2022 | 98.44 |
| 2021 | 98.74 |
| 2020 | 99.03 |
| 2019 | 99.06 |
| 2018 | 98.91 |
| 2017 | 99.22 |
| 2016 | 100.00 |
| 2015 | 100.00 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 5.40 |
| 2024 | 6.30 |
| 2023 | 7.43 |
| 2022 | 8.45 |
| 2021 | 7.78 |
| 2020 | 9.00 |
| 2019 | 15.17 |
| 2018 | 16.14 |
| 2017 | 101.33 |
| 2016 | 223.29 |
| 2015 | 234.60 |
Price/Forward earnings (YTD)
19.84
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | 9.79 |
| 2023 | 8.89 |
| 2022 | 6.96 |
| 2021 | 4.71 |
| 2020 | 26.79 |
| 2019 | 3.22 |
| 2018 | 2.33 |
| 2017 | -24.10 |
| 2016 | -33.60 |
| 2015 | -24.78 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 1.44 |
| 2023 | 1.46 |
| 2022 | 1.39 |
| 2021 | 1.51 |
| 2020 | 1.54 |
| 2019 | 2.05 |
| 2018 | 2.07 |
| 2017 | 2.20 |
| 2016 | 1.16 |
| 2015 | 1.12 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
